Tel.: +34 91 736 2385
LOCAL TIME
Contact: Cristina Miralles
Hours: Mon-Fri 8:30-15:00
07:50
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

BSH 2020 VIRTUAL

 

9-14 November 2020 Virtual Conference
FAQs
   
Discussion forum - BSH 2020 VIRTUAL
    Topic - Lymphoma/CLL

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
  
 Thread / Poster  Author  Replies  Last reply
Structural and functional variability of the tumour B-cell receptor indicates a role for environmental influences on the behaviour of mantle cell lymphoma  David Dutton 1      11/9/2020 10:41:00 PM  
An Analysis of Patients Treated with Weekly Salvage Chemotherapy Regimens forHigh Grade Lymphoma  Seetha Sureshkumar 1      11/9/2020 10:31:00 PM  
Implementing Venetoclax treatment into Day Case setting for patients at High Risk of Tumour Lysis Syndrome; University Hospital Southampton NHS Foundation Trust experience  Klara Matulay 1      11/9/2020 12:01:00 PM  
Systemic ALCL treated in routine clinical practice: survival outcomes following first-line chemotherapy from an international multicentre cohort study  Nicolas Martinez-Calle 1      11/9/2020 12:01:00 PM  
Modeling R-CHOP chemoimmunotherapy in murine lymphoma to characterize and overcome resistance  Bernard Maybury 1      11/9/2020 12:01:00 PM  
Escalated BEACOPDac as first line therapy in 100 Hodgkin lymphoma patients reduces red cell transfusion requirements and may shorten time to menstrual period recovery whilst maintaining efficacy compared to escalated BEACOPP  Anna Santarsieri 1      11/9/2020 12:01:00 PM  
IS THE ALL-ORAL DEVEC METRONOMIC SCHEDULE A BETTER ALTERNATIVE TO INFUSIONAL CHEMOTHERAPY PROTOCOLS IN ELDERLY WITH PERIPHERAL T-CELL LYMPHOMA?  M Christina Cox 1      11/9/2020 12:01:00 PM  
Post discharge care needs for patients with treated Primary CNS Lymphoma a baseline single centre retrospective study  Ekram Omer 1      11/9/2020 12:01:00 PM  
Safety, efficacy and tolerability of the NORDIC regimen in the front-line treatment of transplant-eligible patients with mantle cell lymphoma  Jake Tobin 1      11/9/2020 12:01:00 PM  
Outcomes of patients with refractory Peripheral T-cell lymphoma, Angioimmunblastic and other nodal lymphomas of T follicular helper-cell origin (OPerA)  Waqas Jehangir 1      11/9/2020 12:01:00 PM  
A single centre experience of using ciclosporin and mycophenolate mofetil immunosuppression in relapsed/refractory angio-immunoblastic T cell lymphoma.  KG De 1      11/9/2020 12:01:00 PM  
Impact of Liso-cel Treatment on Health-Related Quality of Life and Health Utility in Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: TRANSCEND NHL 001  Donald Patrick 1      11/9/2020 12:01:00 PM  
Utility of FDG-PET CT-directed splenic biopsy in lymphoma diagnosis  Jawad Saeed 1      11/9/2020 12:01:00 PM  
18Fluoromethylcholine PET/CT: a new tool for CNS lymphoma  Kirsty Marshall 1      11/9/2020 12:01:00 PM  
ACOPP Chemotherapy for Frontline Treatment of Older Patients with Hodgkin Lymphoma - a Pilot Study  Matthew Poynton 1      11/9/2020 12:01:00 PM  
Phase Ib/II Trial of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population  Michael Caruana Dingli 1      11/9/2020 12:01:00 PM  
Anthracycline prescribing in Lymphoma: Traffic light guidance using NT-proBNP and echocardiogram  Kenneth Charles 1      11/9/2020 12:01:00 PM  
Addition of bendamustine to Brentuximab vedotin leads to improved complete metabolic remission rates in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective, single centre series  Annabel Mcmillan 1      11/9/2020 12:01:00 PM  
Real World Outcomes for Treatment of Diffuse Large B cell Lymphoma in Patients aged 80 and over  Rachel Wheeler 1      11/9/2020 12:01:00 PM  
Successful Employment of Spatial Imaging Mass Cytometry in Follicular Lymphoma Confirms a Central Role of Follicular Helper T-Cells in Disease Pathogenesis  Beth Phillips 1      11/9/2020 12:01:00 PM  
Adoption of rapid obinutuzumab infusions: real world experience  Joel Cunningham 1      11/9/2020 12:01:00 PM  
Minimal Residual Disease and the Prediction of Survival Outcomes in Chronic Lymphocytic Leukaemia: A Pooled Analysis of Observational and Clinical Trial Data  Charlotte Johnston 1      11/9/2020 12:01:00 PM  
Contemporary Real-world Treatment Patterns of Chronic Lymphocytic Leukaemia (CLL) in England  Satoshi Hori 1      11/9/2020 12:01:00 PM  
IGHV Analysis Utilising the Ion GeneStudio S5 System and the Oncomine BCR IGH-LR Assay Early Access Experience  Zadie Davis 1      11/9/2020 12:01:00 PM  
Incidence of BTK mutations in chronic lymphocytic leukaemia treated with BTK inhibitors in a single UK institution  Elisa Santambrogio 1      11/9/2020 12:01:00 PM  
Lymph node core biopsy: outcomes from 554 consecutive biopsies and prospective patient experience survey demonstrate a safe, rapid, reliable diagnostic method for lymphoma  Aoife Dervin 1      11/9/2020 12:01:00 PM  
UK CLL Forum 5 year update on 315 relapsed refractory CLL patients treated with ibrutinib in 66 UK and Ireland centres  George Follows 1      11/9/2020 12:01:00 PM  
Finding the five percent: Predicting Adult T-cell Leukaemia/Lymphoma (ATLL) in Human T-cell leukaemia Virus-1 (HTLV-1) carriers using a novel flow cytometric method  Sonia Wolf 1      11/9/2020 12:01:00 PM  
Novel synthetic thienopyridine derivatives induce tubulin disruption and cell cycle arrest in malignant B cells with level of activity related to their chemical structure  Christopher Broughton 1      11/9/2020 12:01:00 PM  
Vaccination Recommendation in Newly Diagnosed Chronic lymphocytic Leukaemia: A Retrospective Audit  Ruby Haji 1      11/9/2020 12:01:00 PM  
INCIDENCE OF CARDIOTOXICITY IN ANTRACYCLINE BASED CHEMOTHERAPY IN LYMPHOMA PATIENTS: A SINGLE CENTRE EXPERIENCE  Charlotte Bloodworth 1      11/9/2020 12:01:00 PM  
Experiences of providing commercial Chimeric Antigen Receptor (CAR-T) cell therapy at the Northern Centre for Cancer Care  Katherine Smith 1      11/9/2020 12:01:00 PM  
The GELOX-radiotherapy sandwich regime is a highly effective outpatient regimen for limited stage Extranodal NK/T cell Lymphoma nasal type with acceptable toxicity  Jawad Saeed 1      11/9/2020 12:01:00 PM  
Local experience of the use of IVE methotrexate chemotherapy for the treatment of systemic T cell lymphoma.  Thomas Fail 1      11/9/2020 12:01:00 PM  
Palliative care needs during inpatient stay for commercial chimeric antigen receptor T-cell infusion at the Newcastle-Upon-Tyne Hospitals NHS Foundation Trust  Katherine Smith 1      11/9/2020 12:01:00 PM  
Btk Inhibitor Ibrutinib Impairs Fcγ947;RIIa-Mediated Responses of Platelets from Healthy Donors and Chronic Lymphocytic Leukaemia Patients to Bacteria.  Leigh Naylor-Adamson 1      11/9/2020 12:01:00 PM  
Outcomes for Patients with Diffuse Large B Cell Lymphoma in the West of Scotland in the pre-CAR-T era  Matthew Poynton 1      11/9/2020 12:01:00 PM  
Risk stratifying patients presenting with lymphadenopathy an audit of 2 week wait referrals for suspected haematological malignancy compared to NICE guidance  Matthew Cant 1      11/9/2020 12:01:00 PM  
Response to brentuximab vedotin plus CHP according to CD30 expression in the ECHELON-2 trial  Harriet Tucker 1      11/9/2020 12:01:00 PM  
Brentuximab vedotin plus chemotherapy for Stage III/IV classical Hodgkin lymphoma: 4-year update of the ECHELON-1 study  Harriet Tucker 1      11/9/2020 12:01:00 PM  
Serial troponin measurement during anthracycline-containing chemotherapy may predict early cardiotoxicity that is amenable to primary prevention with ACE inhibitors  Ipek Cakmak 1      11/9/2020 12:01:00 PM  
Treatment decisions in Waldenstroms Macroglobulinaemia; outcomes from the South East Scotland Cancer Network  AJ Duguid 1      11/9/2020 12:01:00 PM  
Updated Results of a Phase Ib/II Randomised Study: Polatuzumab Vedotin (Pola) Plus Bendamustine (B) and Rituximab (R) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)  Michael Caruana Dingli 1      11/9/2020 12:01:00 PM  
EPIDEMIOLOGY OF HAEMATOLOGICAL MALIGNANCIES IN NATIONAL HOSPITAL ABUJA: A TEN-YEAR RETROSPECTIVE STUDY  Iniabasi David 1      11/9/2020 12:01:00 PM  
Ibrutinib at first relapse for mantle cell lymphoma: a United Kingdom real-world analysis of outcomes in 211 patients  Rory McCulloch 1      11/9/2020 12:01:00 PM  
Lymph node core biopsy: outcomes from 554 consecutive biopsies and prospective patient experience survey demonstrate a safe, rapid, reliable diagnostic method for lymphoma  Aoife Dervin 1      11/4/2020 8:27:00 PM  
Successful Employment of Spatial Imaging Mass Cytometry in Follicular Lymphoma Confirms a Central Role of Follicular Helper T-Cells in Disease Pathogenesis  Beth Phillips 1      11/3/2020 9:47:00 PM  
Novel synthetic thienopyridine derivatives induce tubulin disruption and cell cycle arrest in malignant B cells with level of activity related to their chemical structure  Christopher Broughton 1      11/2/2020 11:59:00 PM  
Post discharge care needs for patients with treated Primary CNS Lymphoma a baseline single centre retrospective study  Ekram Omer 1      11/2/2020 9:52:00 PM  
Ibrutinib at first relapse for mantle cell lymphoma: a United Kingdom real-world analysis of outcomes in 211 patients  Rory McCulloch 1      11/2/2020 8:00:00 PM  
Local experience of the use of IVE methotrexate chemotherapy for the treatment of systemic T cell lymphoma.  Thomas Fail 1      10/30/2020 7:45:00 PM  
A single centre experience of using ciclosporin and mycophenolate mofetil immunosuppression in relapsed/refractory angio-immunoblastic T cell lymphoma.  KG De 1      10/30/2020 1:14:00 PM  
       




Most viewed poster for this congress
Poster: 1
Visits: 415
Title: Whole genome profiling of adult B-other acute lymphoblastic leukaemia on the UKALL14 trial
Authors: Daniel Leongamornlert , E. Barretta, S. Lee, T. Creasey, R. Mitchell, A. A. Kirkwood, L Clifton-Hadley, P. Patrick, P. Campbell, B. Patel, A. Moorman, A. K. Fielding, E. Papaemmanuil
Centre: 

Poster most viewed in this topic
Poster: 81
Visits: 107
Title: Updated Results of a Phase Ib/II Randomised Study: Polatuzumab Vedotin (Pola) Plus Bendamustine (B) and Rituximab (R) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Authors: Elaine Kamara , L.H. Sehn, M.J. Matasar, C.R. Flowers, M. Kamdar, A.K. McMillan, M. Hertzberg, S. Assouline, T.M. Kim, W.S. Kim, M. Ozcan, B. Croft, J. Hirata, J. Cheng, G. Ku, A.F. Herrera
Centre: 


 




PosterSessionOnline
Logo Draft
 
Logo Cert